BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 23084329)

  • 1. Natural history of early, localized prostate cancer: a final report from three decades of follow-up.
    Popiolek M; Rider JR; Andrén O; Andersson SO; Holmberg L; Adami HO; Johansson JE
    Eur Urol; 2013 Mar; 63(3):428-35. PubMed ID: 23084329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden.
    Akre O; Garmo H; Adolfsson J; Lambe M; Bratt O; Stattin P
    Eur Urol; 2011 Sep; 60(3):554-63. PubMed ID: 21664039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
    Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards an optimal interval for prostate cancer screening.
    van Leeuwen PJ; Roobol MJ; Kranse R; Zappa M; Carlsson S; Bul M; Zhu X; Bangma CH; Schröder FH; Hugosson J
    Eur Urol; 2012 Jan; 61(1):171-6. PubMed ID: 21840117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
    Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population.
    Orsted DD; Nordestgaard BG; Jensen GB; Schnohr P; Bojesen SE
    Eur Urol; 2012 May; 61(5):865-74. PubMed ID: 22104593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural history of early, localized prostate cancer.
    Johansson JE; Andrén O; Andersson SO; Dickman PW; Holmberg L; Magnuson A; Adami HO
    JAMA; 2004 Jun; 291(22):2713-9. PubMed ID: 15187052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.
    Godtman RA; Holmberg E; Khatami A; Pihl CG; Stranne J; Hugosson J
    Eur Urol; 2016 Nov; 70(5):760-766. PubMed ID: 27090975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987.
    Jonsson E; Sigbjarnarson HP; Tomasson J; Benediktsdottir KR; Tryggvadottir L; Hrafnkelsson J; Olafsdottir EJ; Tulinius H; Jonasson JG
    Scand J Urol Nephrol; 2006; 40(4):265-71. PubMed ID: 16916765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis.
    Briganti A; Spahn M; Joniau S; Gontero P; Bianchi M; Kneitz B; Chun FK; Sun M; Graefen M; Abdollah F; Marchioro G; Frohenberg D; Giona S; Frea B; Karakiewicz PI; Montorsi F; Van Poppel H; Jeffrey Karnes R;
    Eur Urol; 2013 Apr; 63(4):693-701. PubMed ID: 22959192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The 20-Yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity.
    Adolfsson J; Tribukait B; Levitt S
    Eur Urol; 2007 Oct; 52(4):1028-35. PubMed ID: 17467883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies.
    Schröder FH; van den Bergh RC; Wolters T; van Leeuwen PJ; Bangma CH; van der Kwast TH; Roobol MJ
    Eur Urol; 2010 Feb; 57(2):256-66. PubMed ID: 19913350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
    Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
    BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
    BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial).
    Schröder FH; Kurth KH; Fossa SD; Hoekstra W; Karthaus PP; De Prijck L; Collette L
    Eur Urol; 2009 Jan; 55(1):14-22. PubMed ID: 18823693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 20-year outcomes following conservative management of clinically localized prostate cancer.
    Albertsen PC; Hanley JA; Fine J
    JAMA; 2005 May; 293(17):2095-101. PubMed ID: 15870412
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden.
    Johansson JE; Holmberg L; Johansson S; Bergström R; Adami HO
    JAMA; 1997 Feb; 277(6):467-71. PubMed ID: 9020270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple events of fractures and cardiovascular and thromboembolic disease following prostate cancer diagnosis: results from the population-based PCBaSe Sweden.
    Van Hemelrijck M; Garmo H; Holmberg L; Stattin P; Adolfsson J
    Eur Urol; 2012 Apr; 61(4):690-700. PubMed ID: 21945719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study.
    Bul M; Zhu X; Valdagni R; Pickles T; Kakehi Y; Rannikko A; Bjartell A; van der Schoot DK; Cornel EB; Conti GN; Boevé ER; Staerman F; Vis-Maters JJ; Vergunst H; Jaspars JJ; Strölin P; van Muilekom E; Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2013 Apr; 63(4):597-603. PubMed ID: 23159452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.